Hoth Therapeutics, Inc. (HOTH)
Chart Events
Performance Outlook
| Previous Close | 1.9300 |
| Open | 1.9600 |
| Bid | 1.8200 x 800 |
| Ask | 1.8700 x 1400 |
| Day's Range | 1.7100 - 1.9600 |
| 52 Week Range | 1.5600 - 7.0000 |
| Volume | 1,392,250 |
| Avg. Volume | 4,272,149 |
| Market Cap | 29.442M |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8980 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
Fair Value
Related Research
- PR Newswire
Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today provided an update on preclinical study on HT-002 for the prevention and/or treatment of Sars-CoV-2, or COVID-19.
- PR Newswire
Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.
- PR Newswire
Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its licensing agreement from North Carolina State University ("NC State") to include the worldwide development and commercialization of treatments targeting mast cell derived cancers and anaphylaxis.
